Navigation Links
Gene Therapy Eradicates Pancreatic Cancer in Mice

Researchers at the University of Texas M. D. Anderson Cancer Center have found in pre-clinical trials that a molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumours, inhibits metastasis, and prolongs survival virtually without toxicity.

"This vehicle, or vector, is so targeted and robust in its cancer-specific expression that it can be used for therapy and perhaps for imaging," notes senior author Dr. Mien-Chie Hung, Professor and Chair of Department of Molecular and Cellular Oncology at the institution.

In a report published in the journal Cancer Cell, the researchers have described the system as a versatile expression vector-nicknamed VISA. It includes a targeting agent that is also called a promoter, two components that boost gene expression in the target tissue, and a payload that is a gene known to kill cancer cells in this case.

All these are packaged in a fatty ball called liposome, and delivered through veins.

"This looks like a promising approach to gene therapy for pancreatic cancer and we are working to bring it to a clinical trial," says Dr. James Abbruzzese, Professor and Chair of the M. D. Anderson Department of Gastrointestinal Oncology.

It may take around one to two years to complete U.S. Food and Drug Administration requirements for a Phase I trial, he says.

In a study, the researchers loaded the VISA system with a mutant version of a gene named BiK, which expresses a protein that naturally forces cancer cells to kill themselves, in two different types of mice. Boffins created the more lethal mutant and named it BikDD.

Untreated control mice in both experiments all died within 40 days, while mice treated with the mutant gene delivered via a less-targeted viral promoter driven expression system employing cytomegalovirus (CMV) died within 90 days. However, the VISA-BikDD mice lived longer in b oth trials, with at least half surviving for 14 months with no detectable sign of cancer recurrence.

The researchers involved a pancreatic cancer line that spreads swiftly, in one test. They say that live imaging showed that in control mice the cancer spread to the liver, spleen, kidneys, bladder, lungs, bone, and intestines. But mice treated with the CMV BikDD showed only a few small tumours in nearby organs.

There were no detectable metastases in mice treated with the VISA-BikDD combination.

"All cancer drugs have some toxicity and so cause side effects, which affects the dose that can be administered. The VISA-BikDD produces virtually no systemically acute toxicity or acute pancreatitis," the authors report.

Dr. Abbruzzese says that the phase I clinical trial will advance under a National Cancer Institute Specialized Programs of Research Excellence (SPORE) grant in pancreatic cancer. SPORE awards are designed to translate scientific findings into the clinic.

"There are no good options for pancreatic cancer patients now. That's why we are trying new approaches such as this one as part of SPORE," says Dr. Abbruzzese.


'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology: